Funding at all levels makes a significant difference to our small charity 

  • This can be a one-off, repeat or multi-year commitment.
  • Donations may range from several hundred pounds to tens of thousands of pounds per year, and allow partial or full funding of highly prestigious projects.

Our major donors can choose to dedicate their bequest to a specific field of research or Vascular Campaign. For example: -

Aneurysms (swellings in arteries).

80% of people with burst Aortic Aneurysms die. Aneurysms form in any artery and if they are not detected can burst, however if they are discovered in time 95% of people survive. Therefore more research is need in this including investigations into methods of detection and treatment, and population and genetic studies to determine those at risk.

There is also opportunities to further develop the current very successful Aortic aneurysm screening programme which detects aneurysm early hence leading to successful treatment.

Blocked arteries

These can cause death by stroke, heart disease, gangrene or kidney disease and account for the majority of amputations in the UK. Partial blockage or rupture of arteries in and around the head can cause blindness. We need research into new methods for detecting the blockages and relieving them. We are also concerned with the premature ageing of arteries particularly in people with diabetics.

Venous disease

We still do not know why 1 in 5 women and 1 in 10 men get varicose veins more research is needed.

Venous ulcers can be hugely debilitating and can take months to heal and we still do not know why they occur. They require frequent care and attention to stop them from getting infected and endangering the patient. 

Rehabilitation and Nursing

To improve the quality of life for sufferers of Vascular disease we need to continue to develop rehabilitation ideas, aids, and devices, which may include intensive care monitoring equipment, beds, wheelchairs, specialist exercise regimes or health education programmes. Funding is essential to maintain progress in these areas and to support the rigorous independent testing and pilot schemes required before patients can benefit from these innovations.

We are most grateful for the generous support